XXXX in the therapy of @entity2954 .

@entity1 @entity2954 @entity6368 @entity4258 @entity281 @entity1536
@entity4258 is a @entity1536 derivative with demonstrated activity against @entity6368 . The MIC90 against penicillinase- and non-penicillinase producing @entity6368 is 0.06 mg/l and 0.015 mg/l respectively. The drug is rapidly absorbed with a single oral dose of 800 mg producing peak serum levels of 2.45 mg/l. In this open, uncontrolled study, 70 @entity1 with laboratory confirmed, uncomplicated @entity281 with @entity6368 were entered to determine the efficacy and safety of a single oral dose of @entity4258 800 mg. Thirty-one males and 27 females were evaluated for efficacy with 34 males and 25 females evaluated for safety. @entity4258 cured all 31 urethral and two pharyngeal @entity281 in @entity1 . All 25 females with endocervical @entity281 and six with rectal involvement were also cured. The single treatment failure occurred in a @entity1 who had persistent pharyngeal infection. All isolates of @entity6368 were inhibited by 0.05 mg/l of @entity4258 . The incidence of adverse effects was 23.7% but all were mild, required no specific therapy and cleared without sequelae. In this study, @entity4258 proved to be an effective agent in the therapy of uncomplicated @entity2954 in males and females. It has previously been proven to be useful in the therapy of @entity2954 due to penicillinase-producing @entity6368 and the value of this drug as a first line choice in the treatment of @entity2954 is discussed.
